文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > 临床医学 > 替米沙坦对急性卒中预后复发的作用
侵权投诉

替米沙坦对急性卒中预后复发的作用

3542StrokeNovember2009

icaloutcomeswereanalyzedusingordinalstatisticalapproaches.21,22Tolerabilitywasmeasuredbyadherencetotherapy.

artan(ARA)withplacebo,andaspirin-extendedreleasedipyridamolewithclopidogrel,inpreventingrecurrentstroke.19Akeyintentionoftheprotocolwastorecruitthepatientatatimewhentheriskofrecurrencewasparticularlyhigh;1939.9%patientswererecruitedwithin10daysoftheindexevent.2Also,1360(6.7%)ofpatientswererecruitedwithin72hoursofstrokeonset,therebyprovidingtheopportunitytoassess,inarandomizeddesign,thesafetyandefficacyofloweringbloodpressurewithtelmisartan(ontopofstandardpoststrokeantihypertensivetreatment)inpatientswithacuteischemicstroke.

Analyses

Dataareshownasthenumberofsubjects(%)ormean(SD).Comparisonswereperformedwithbinarylogisticregression(dichot-omousdata),ordinallogisticregression,ortheMann–WhitneyUtest(orderedcategoricaldata),ormultipleregression(continuousdata).Statisticalmodelswereadjustedforprognosticcovariates:baselineage,sex,severity,andSBP,andantiplatelettreatmentassignment(aspirin/dipyridamolevsclopidogrel).OR(95%CI)areshownandstatisticalsignificancewassetatP 0.05.AnalyseswereperformedusingSASversion9.1.

MaterialsandMethods

ThePRoFESStrialprotocolandprimaryresultshavebeenpublished.Briefly,PRoFESScomparedtheeffectofloweringBPwithtelmisartan(ARA,80mgdaily)vsplacebo,andcombinedaspirin(25mgtwicedaily)andextendedreleasedipyridamole(200mgtwicedaily)vsclopidogrel(75mgdaily),ina2 2factorialdesign,inpatientswithrecentischemicstroke.Over34months,20332patientswererandomizedfrom695centersin35countriesandfollowed-upforameandurationof30months.Allpatientsreceivedbestmedicalcareindependentoftreatmentassignment;inparticular,thePRoFESSstudyprotocolmandatedthatallpatientswithhypertensionshouldbetreatedwithanappropriateBP-loweringmedication,excludinganARA,withatargetbloodpressureof 140/90mmHg.

19

1,2

Results

ThissubgroupanalysisofthePRoFESStrial1,2examinedtheclinicalusefulnessofaddingtelmisartanvsplacebotostan-dardpoststrokeantihypertensivetreatmentin1360patients(telmisartan647,placebo713)recruitedwithin72hoursofstrokeonset(supplementalFigureI,availableonlineatdoc.guandang.net).Themeantimefromstroketorecruit-mentwas58hours,withthemajorityofpatientsrecruitedduringthethirddayafterstrokeonset;treatmentwasstartedwithin3daysofstrokein853patients(63%)andwithin4daysin1250(92%).Thecharacteristicsofpatientsinthisanalysiswerebroadlysimilartothoseofthewholetrial(Table1).ThemeanbaselineBPwas147/84mmHg,andseveritywasmildwithNIHSS 3.Thetreatmentgroupsweresimilarfordemographic,clinical,andhemodynamicmeasures(Table1).

InclusionCriteria

TheaimofthisPRoFESSsubgroupanalysis,whichwasnotprespecifiedinthestatisticalanalysisplan,wastoassessthesafetyandefficacyofloweringBPwithtelmisartaninpatientswithacutestroke.Patientswereincludediftheywereenrolledinthemaintrialandhadbeenrandomizedwithin72hoursofstrokeonset.Thetimeof72hourswaschosenaprioritomirrorthedesignoftheACCESStrialofcandesartan,anotherARA.15SomePRoFESSinclusioncriteriaarerelevantspecificallytoassessmentofBPmanagementinacutestroke:ischemicstroke;symptomspersistingfor 24hours,orif 24hoursthenCTorMRIevidenceofanewstroke;hospital-ization;ageolderthan55years,orage50to54yearsif2additionalvascularriskfactorspresent;seatedsystolicBP(SBP)121to180mmHg;seateddiastolicBP 110mmHg;andneurologicallystable.Similarly,relevantkeyexclusioncriteriaare:dysphagiapreventingoralmedication;severedependencyattimeofrandom-ization(modifiedRankinScale[mRS] 3);currentlyusingorneedingARA;knownsevererenalinsufficiencyorrenalarterystenosis;hyperkalemia;uncorrectedvolumeorsodiumdepletion;knownseverecoronaryarterydiseaseorrecentMI;andpatientsscheduledforcarotidendarterectomy.

BP

Incomparisonwithplacebo,telmisartanloweredBPsignifi-cantlyby6to7mmHgand2to4mmHgoverthe90days(Table2).Parallelreductionsinpulsepressureandrate-pressureproductwerepresent.Noeffectonheartratewasseen.

Outcome

Combineddeathordependency(mRSat30daysafterrandomization,withadjustmentforbaselinecovariates)didnotdifferwhetheranalyzedasanordinaloutcome(orderedmRScategories:0,1,2,3,4–6tomaintainproportionality)21(OR,1.03;95%CI,0.84–1.26;P 0.81;Figure1)orwithdichotomizationofthedataatthemedian(mRS0–1vs2–6;OR,1.00;95%CI,0.77–1.29;Table3).Nosubgroupsshoweddifferentialtreatmenteffects(supplementalFigureII,availableonlineatdoc.guandang.net).

Thedistributionofordinalstrokeevents(fatal,dependent[mRS2–5],independent[mRS0,1],TIA,none)22didnotdifferbetweenthetreatmentgroups(Mann–WhitneyUtest,P 0.42;Figure2).Similarly,thetimetorecurrencedidnotdifferbetweenthetreatmentgroups(log-ranktest,P 0.40).Similarly,otherevents(ie,death,strokerecurrence,MI,andcombinedvascularevents)didnotdifferbetweenthetreatmentgroups,whethermeasuredat7,30,or90days(Table3).TherewasnodifferenceintheMini-MentalStateExaminationat30days.

HemodynamicMeasures

SBP,diastolicBP,andheartrate(HR)weremeasuredusingavalidatedsemiautomaticmonitor(Omron705CP).20Otherhemody-namicvariableswerederivedmathematicallyfromBPandHR:Pulsepressure SBP diastolicBPSBPvariability SDofSBP/meanSBP

Ratepressureproduct(measureofcardiacwork) SBP HR

Outcomes

TheprimaryoutcomeinthisposthocsubgroupanalysiswasfunctionaloutcomemeasuredusingthemRSat30daysafterrandomization;amoreconventionaltrialtimeof90dayswasnotpossiblebecausemRSwasnotmeasuredatthispoint.Secondaryoutcomeswerestudiedat7,30,and90days(therebymimickingthedesignofmanyacutestroketrials)andincludedhemorrhagictransformationoftheinfarct,cerebraledema,recurrentstroke,MI,compositevascularevents(vasculardeath,nonfatalstroke,orMI),death,andseriousadverseevents.Whenpossible,orderedcategor-

SeriousAdverseEvents

Seriousadverseeventsweresimilarbetweentelmisartanandcontrol(Table3;fatal,5vs6;nonfatal,45vs33).Selectedseriousadverseeventsrelevanttostroke,BP-lowering,or

上一页第2页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email